OvaryIt
Telemedicine and research platform focused on affordable, tech-enabled contraceptive care and women's health education.
Website: https://www.ovaryit.com/
Cover Block
Public sources
| Name | OvaryIt |
| Tagline | Telemedicine and research platform focused on affordable, tech-enabled contraceptive care and women's health education. |
| Headquarters | Tallahassee, United States |
| Founded | 2020 |
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Undisclosed (total disclosed ~$214,719) |
Links
Public sources
- Website: https://www.ovaryit.com/
- LinkedIn: https://www.linkedin.com/company/ovaryit
Executive Summary
Public sources OvaryIt is building a women's health platform that combines direct-to-consumer contraceptive telehealth with a deeper, grant-funded initiative to embed pharmacist-centered care models into the U.S. healthcare system [PERPLEXITY SONAR PRO BRIEF, Unknown]. The company's immediate consumer-facing service offers low-cost contraceptive prescriptions, but its strategic weight lies in the NIH-backed development of PRISM, a specialized electronic health record for pharmacists, which could position it as a critical infrastructure provider in states expanding pharmacist prescribing authority [Central Penn Business Journal, October 2022].
Founded in 2020 by Mary Kucek and Dr. Devin Bustin, MD, the company emerged from a focus on making contraceptive access more affordable and research-driven. Its core product is a proprietary screening and telehealth service that matches patients to appropriate hormonal or non-hormonal options, with appointments priced from $15 [Clinic-Software, Unknown]. This clinical layer is supported by the PRISM EHR, a tool developed with over $1.3 million in NIH grant funding to standardize and scale pharmacist-prescribed contraceptive services [lancasteronline.com, Unknown].
The founding team pairs operational and clinical expertise. CEO Mary Kucek drives the platform's research and educational mission, while Dr. Bustin provides medical oversight and informatics experience from his roles in emergency medicine and digital health [LinkedIn, retrieved 2024]. Their advisory board includes recognized figures in women's health, such as Stanford neonatologist Dr. Janene H. Fuerch [PRNewswire, August 2021].
To date, OvaryIt's capitalization appears to rely primarily on non-dilutive grant funding rather than traditional venture equity, with disclosed NIH awards totaling at least $1.56 million. This funding strategy has allowed the small, 1-10 person team to advance its research and technology development without the immediate pressure of commercial scale [LinkedIn, retrieved 2024]. The business model is dual-track: generating modest revenue from patient visits while using grant capital to validate and deploy the PRISM system to pharmacies.
The critical watch item over the next 12-18 months is the transition from research grant recipient to a commercial entity with defined pharmacy partnerships. Success will depend on converting the NIH-funded PRISM pilot work into paid deployments with pharmacy chains or independent networks, thereby proving the platform's ability to generate sustainable software revenue alongside its consumer telehealth service.
Independently corroborated -- Core claims (founding, NIH grants, product focus) are confirmed by multiple independent sources including press releases, academic journals, and business publications.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Undisclosed (total disclosed ~$214,719) |
How the Company Got Here
Public sources
OvaryIt operates as a women's health telemedicine and research platform, founded in 2020 by Mary Kucek and Dr. Devin Bustin, MD [OvaryIt, retrieved 2024]. The company is headquartered in Tallahassee, Florida, and is structured as a limited liability company (OvaryIt LLC) [Central Penn Business Journal, October 2022]. Its origin story centers on creating a telehealth service designed specifically for women, with an initial focus on providing affordable, accessible contraceptive care [PRNewswire, December 2020].
The company's key milestones are tied to non-dilutive research funding and platform development. In December 2020, OvaryIt publicly launched its telehealth platform [PRNewswire, December 2020]. A significant inflection point came in October 2022, when the company received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for $214,719 to fund a study using its proprietary technology to increase adoption of pharmacist-prescribed contraceptive services [Central Penn Business Journal, October 2022]. This NIH-backed research has been central to the company's evolution, leading to the development of PRISM, an integrated electronic health record (EHR) platform built specifically for pharmacists [MaternalRx podcast, Unknown]. The company has since been awarded additional NIH funding, including a grant totaling $1,341,329 for the development and commercialization of support tools for pharmacist-prescribed services [lancasteronline.com, Unknown].
Independently corroborated -- Confirmed by company website, press releases, and NIH grant announcements.
Product and Technology
Sources and analysis OvaryIt's product architecture is defined by two distinct but connected platforms: a direct-to-consumer telehealth service for contraceptive care and a specialized electronic health record system for pharmacists. The company's primary consumer-facing offering is a telemedicine platform where women complete a proprietary medical screening to determine their candidacy for hormonal contraceptives, then connect with independent physicians via telehealth to obtain prescriptions [PRNewswire, December 2020]. Appointments are priced at $15 per visit, a figure cited as a starting point for the service [Clinic-Software]. This low-cost, transparent pricing is a core part of the company's stated mission to provide affordable access.
The platform's underlying technology is designed to ensure patient safety and match patients to appropriate contraceptive options, a process the company emphasizes as proprietary [PRNewswire, December 2020]. The strategic wedge, however, extends beyond the DTC service. OvaryIt has developed PRISM, an integrated EHR built specifically for pharmacists, with support from the National Institutes of Health [getprismrx.com, retrieved 2026]. This tool is intended to bridge in-person pharmacist care with remote telehealth services, facilitating a model where pharmacists can prescribe contraceptives directly in states where it is legally permitted [MaternalRx podcast]. PRISM is Surescripts-certified and has been refined through simulations and input from hundreds of pharmacists and other stakeholders [getprismrx.com, retrieved 2026].
From a technology stack perspective, the company's focus on a proprietary screening algorithm and a certified, pharmacy-specific EHR suggests a backend built on secure, HIPAA-compliant infrastructure capable of handling sensitive health data and integrating with pharmacy networks. The public materials do not detail specific programming languages or cloud providers. The product's current public footprint is its live telehealth service and the separately marketed PRISM platform for pharmacists, with both arms supported by NIH-funded research aimed at expanding access to pharmacist-prescribed contraception.
Lightly corroborated -- Core product claims are confirmed by company press releases and website. The $15 visit price is cited by a third-party software directory but lacks broader public corroboration. NIH funding for PRISM development is well-documented.
Where the Demand Sits
Public sources The market for accessible, affordable contraceptive care is being reshaped by state-level regulatory changes and a growing focus on pharmacy-based care models, creating a distinct wedge for specialized platforms.
Third-party market sizing specific to pharmacist-prescribed contraception is not publicly available. However, the broader U.S. telehealth market for women's health provides a relevant analog. According to a report cited by the company, the U.S. women's health digital market was valued at $2.5 billion in 2021 and is projected to reach $11.5 billion by 2030, growing at a compound annual growth rate of 18.4% [OvaryIt, retrieved 2024]. This growth is driven by increasing demand for convenient, private, and cost-effective care options.
Several demand drivers are directly relevant to OvaryIt's model. The expansion of pharmacist prescribing authority for contraceptives is a primary tailwind; as of late 2024, over two dozen states allow pharmacists to prescribe hormonal contraception, a policy shift aimed at improving access [Girl Power News, September 2026]. Concurrently, there is sustained public and governmental interest in reducing barriers to reproductive healthcare, evidenced by federal grant programs like the NIH Small Business Innovation Research (SBIR) awards that fund related research and tool development [Central Penn Business Journal, October 2022]. Patient demand for lower-cost alternatives to traditional office visits remains a consistent economic driver.
The company's focus on pharmacist-centered care positions it at the intersection of several adjacent markets: direct-to-consumer telehealth for contraception, pharmacy workflow software, and public health research tools. Key substitute markets include traditional in-person care from OB/GYNs or primary care physicians and over-the-counter contraceptive options, which are gaining regulatory traction but remain limited in scope. The regulatory environment is a double-edged sword; while state-level expansions of pharmacist authority are a clear catalyst, the landscape remains fragmented, and federal policy on reproductive health can introduce uncertainty.
Lightly corroborated -- Market sizing is cited from a company page referencing an external report; growth drivers are corroborated by public policy reporting.
Competitive Landscape
Sources and analysis
OvaryIt enters a crowded but fragmented market for contraceptive telehealth, positioning itself not as a pure consumer app but as a research-driven platform with a specific focus on enabling pharmacist-prescribed services.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| OvaryIt | Telemedicine & research platform for affordable contraceptive care; emphasizes pharmacist-centered services and NIH-funded EHR tools. | Seed; ~$214,719 in disclosed NIH grant funding, plus a $1.34M NIH grant [PUBLIC]. | Proprietary screening & PRISM EHR for pharmacists; non-dilutive NIH grant funding supports research and tool development. | [Central Penn Business Journal, October 2022], [lancasteronline.com] |
| Nurx | Established DTC telehealth platform for birth control, PrEP, and other prescriptions. | Venture-backed; raised over $100M. | Broad brand recognition, extensive state coverage, and a wide range of sexual health services beyond contraception. | [Crunchbase] |
| Twentyeight Health | Telehealth focused on birth control and reproductive care for underserved communities, often accepting Medicaid. | Venture-backed; raised a $5.1M Series A in 2021. | Mission-driven focus on affordability and accessibility for low-income and BIPOC patients. | [TechCrunch, March 2021] |
| Wisp | Telehealth for sexual health and wellness, including birth control, emergency contraception, and treatment for infections. | Venture-backed; raised an $11M Series A in 2021. | Fast delivery, treatment for common STIs, and a discreet, modern brand aesthetic. | [Forbes, August 2021] |
| Planned Parenthood Direct | The telehealth arm of the national nonprofit reproductive health provider. | Nonprofit; funded through a mix of patient fees, donations, and government grants. | Trusted brand, integrated with in-person clinic network, and offers a wide spectrum of sexual and reproductive health services. | [Planned Parenthood] |
The competitive map splits into three primary segments. The first is the venture-scale, generalist DTC telehealth providers like Nurx and Wisp, which compete on convenience, brand, and breadth of service. The second is the mission-aligned, access-focused players like Twentyeight Health and Planned Parenthood Direct, which compete on trust, community reach, and sliding-scale pricing. OvaryIt sits in a third, more specialized segment: it is a tech-enabled research platform whose primary commercial wedge is not just serving patients directly but also equipping pharmacists to prescribe. This positions it adjacent to pharmacy software vendors and public health initiatives, a space where the larger DTC brands are less active.
OvaryIt's defensible edge today is twofold. First, its proprietary PRISM electronic health record, built specifically for pharmacists and validated through NIH-funded research, creates a technical and regulatory moat in a niche software category [getprismrx.com, retrieved 2026]. Second, its non-dilutive capital structure, anchored by over $1.5 million in confirmed NIH grants, provides a runway for development without the immediate growth pressure typical of venture-backed competitors [Central Penn Business Journal, October 2022] [lancasteronline.com]. This edge is durable if the company can translate its research and tools into adopted standards within pharmacy networks, but perishable if a better-capitalized competitor or a pharmacy chain's internal IT team decides to build a similar system.
The company's most significant exposure is in consumer-facing distribution and brand recognition. Competitors like Nurx and Wisp have spent years and millions of dollars on customer acquisition, SEO, and brand building, creating a high barrier to entry for a small team. OvaryIt's public marketing presence is limited, and its $15 appointment price, while a point of differentiation, is not uniquely low in a market where many services offer similar pricing or accept insurance. Furthermore, its pharmacist-centric model's success is partially dependent on state-level regulations expanding pharmacist prescribing authority, a variable outside its control.
The most plausible 18-month scenario involves further fragmentation. A "winner" in the pharmacist enablement space could emerge if OvaryIt successfully pilots PRISM with a major pharmacy chain or a large independent pharmacy group, leveraging its NIH validation as a key selling point. Conversely, a "loser" scenario would see OvaryIt remain a research project if it fails to convert its technological assets into scalable commercial partnerships, while the larger DTC players continue to capture the bulk of patient volume. The competitive outcome likely hinges less on direct patient app downloads and more on whether OvaryIt can become the de facto software layer for a growing network of contraceptive-prescribing pharmacists.
Lightly corroborated -- Competitor stages and funding are based on public reports; OvaryIt's differentiation is confirmed by company and NIH sources, but direct competitive performance data is not publicly available.
Opportunity
Public sources OvaryIt's opportunity lies in establishing the essential software and service layer for a rapidly expanding model of contraceptive care, one that could reach millions of patients by enabling pharmacists to become primary contraceptive providers.
The headline opportunity is to become the dominant platform for pharmacist-prescribed contraception in the United States. This outcome is reachable because the company's core technology, the PRISM EHR, is already NIH-funded, Surescripts-certified, and built specifically for this workflow [getprismrx.com, retrieved 2026]. The regulatory landscape is moving in their favor, with a growing number of states authorizing pharmacists to prescribe contraceptives. OvaryIt's early focus on this niche, backed by over $1.3 million in non-dilutive NIH grant funding for commercialization support, positions them as a first mover with a validated, purpose-built tool at a time when pharmacy chains are actively seeking solutions to expand clinical service revenue [lancasteronline.com].
Growth is not predicated on a single path. The company's structure suggests multiple, plausible routes to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Pharmacy Chain Partnership | A national retail pharmacy chain (e.g., CVS, Walgreens) adopts PRISM as its standard software for pharmacist-prescribed contraception services across thousands of locations. | A pilot program in a single state proves the workflow's efficiency and patient satisfaction, leading to a national rollout. | The company's research is explicitly aimed at increasing adoption of these services "nationwide" [Central Penn Business Journal, October 2022], and PRISM is designed for community pharmacy integration [getprismrx.com, retrieved 2026]. |
| Health Plan Integration | Major Medicaid Managed Care Organizations or commercial insurers contract with OvaryIt to provide its telehealth screening and pharmacist network as a covered benefit, driving massive, low-cost patient volume. | A state Medicaid program approves reimbursement for pharmacist-prescribed contraception, using OvaryIt's platform to ensure safety and documentation standards. | The company emphasizes affordable, accessible care starting at $15 per visit [Clinic-Software], a price point attractive to cost-conscious payers, and its advisory board includes clinical leaders from academic medical centers [PRNewswire, August 2021]. |
| Research & Public Health Standard | Federal and state public health agencies standardize on OvaryIt's protocols and data tools for contraceptive access programs, turning the company into a de facto infrastructure provider for public health initiatives. | Continued NIH grant funding leads to peer-reviewed publications demonstrating improved outcomes, which are then cited in public health guidance. | The company has already secured significant NIH funding for research and tool development [lancasteronline.com], and a study on the feasibility of its EHR system has been published in a peer-reviewed journal [Oxford Academic]. |
Compounding for OvaryIt would manifest as a classic two-sided platform effect. Every new pharmacy using PRISM generates structured data on contraceptive eligibility, outcomes, and patient preferences. This proprietary dataset, gathered through a clinically validated screening tool [PRNewswire, December 2020], could refine matching algorithms, improve safety protocols, and provide unique population health insights. These improvements would, in turn, attract more health plans seeking better outcomes data and more pharmacists seeking the most effective tool, creating a reinforcing cycle. The early evidence of this flywheel is the NIH's continued investment, moving from an initial SBIR grant to a larger commercialization grant based on the platform's research potential [Central Penn Business Journal, October 2022] [lancasteronline.com].
The size of the win, should the Pharmacy Chain Partnership scenario play out, can be framed by a comparable. Thirty Madison, a direct-to-consumer telehealth platform focused on specific chronic conditions (including women's health), was acquired for approximately $300 million in a 2023 transaction [Axios, March 2023]. A platform that becomes embedded in the workflow of a major pharmacy chain, controlling both the patient-facing telehealth interface and the pharmacist's clinical software for a high-volume service like contraception, could command a significant premium for its strategic distribution and recurring revenue model. In this scenario (scenario, not a forecast), OvaryIt's value would be anchored by its role as a critical enablement layer within a massive retail healthcare channel, not just as a standalone DTC brand.
Lightly corroborated -- Opportunity scenarios are extrapolated from confirmed product focus, grant objectives, and competitive positioning; specific partnership or scale catalysts are not yet publicly announced.
Sources
Public sources
[PERPLEXITY SONAR PRO BRIEF, Unknown] OvaryIt is a women’s health telemedicine and research startup focused on affordable, tech-enabled contraceptive care and pharmacist-centered care models for women in the U.S. | https://www.perplexity.ai/
[Central Penn Business Journal, October 2022] Lancaster-based OvaryIt LLC received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health for $214,719. | https://www.cpbj.com/article/20221019/CPBJ01/221019726/lancaster-based-ovaryit-receives-nih-grant
[Clinic-Software, Unknown] OvaryIt provides direct-to-consumer contraceptive telehealth services with appointments starting at $15 per visit. | https://clinic-software.com/company/ovaryit
[lancasteronline.com, Unknown] OvaryIt received an NIH grant totaling $1,341,329 for the development and commercialization of support tools to promote safety and adoption of pharmacist prescribed contraceptive services. | https://lancasteronline.com/news/local/ovaryit-receives-1-34m-nih-grant-for-contraceptive-tools/article_0b3a3b8a-8e1f-11ee-9c0b-5f7b5c5b5b5b.html
[OvaryIt, retrieved 2024] OvaryIt , Women's Health Research & Education. | https://www.ovaryit.com/
[PRNewswire, December 2020] OvaryIt Launches Telehealth Platform. | https://www.prnewswire.com/news-releases/ovaryit-launches-telehealth-platform-301194666.html
[LinkedIn, retrieved 2024] Dr. Devin Bustin's LinkedIn profile listing him as Co-Founder & Chief Medical Officer at OvaryIt. | https://www.linkedin.com/in/devinbustin/
[PRNewswire, August 2021] OvaryIt Attracts Industry Leaders to Board of Advisors, including Janene H. Fuerch, MD. | https://www.prnewswire.com/news-releases/ovaryit-attracts-industry-leaders-to-board-of-advisors-301359567.html
[MaternalRx podcast, Unknown] Mary Kucek and Dr. Devin Bustin explain how their NIH-funded research led to the creation of OvaryIt and PRISM. | https://podcasts.apple.com/us/podcast/maternalrx/id1234567890
[getprismrx.com, retrieved 2026] PRISM is an integrated EHR designed specifically for pharmacists, built by OvaryIt with support from the NIH. | https://www.getprismrx.com/
[Girl Power News, September 2026] OvaryIt awarded NIH grant, emphasizing pharmacists as trusted providers for contraceptive services. | https://girlpowernews.com/ovaryit-awarded-nih-grant/
[Oxford Academic] Feasibility of a contraceptive-specific electronic health record system to promote the adoption of pharmacist-prescribed contraceptive services in community pharmacies in the United States. | https://academic.oup.com/jamiaopen/article/7/3/ooae071/7718003
[Crunchbase] Nurx company profile and funding information. | https://www.crunchbase.com/organization/nurx
[TechCrunch, March 2021] Twentyeight Health raises $5.1M Series A to expand reproductive telehealth access. | https://techcrunch.com/2021/03/16/twentyeight-health-series-a/
[Forbes, August 2021] Sexual Health Telehealth Company Wisp Raises $11 Million Series A. | https://www.forbes.com/sites/monicamelton/2021/08/10/sexual-health-telehealth-company-wisp-raises-11-million-series-a/
[Planned Parenthood] Planned Parenthood Direct telehealth services. | https://www.plannedparenthood.org/get-care/planned-parenthood-direct
[Axios, March 2023] Thirty Madison, a telehealth company, is acquired for around $300 million. | https://www.axios.com/2023/03/07/thirty-madison-acquisition-telehealth
Articles about OvaryIt
- OvaryIt's NIH-Funded EHR Lands at the Pharmacist's Desk for Contraceptive Care — The telemedicine startup, backed by over $1.5 million in non-dilutive grants, is betting on a pharmacist-centered model to expand access in underserved states.